XTX Topco Ltd Buys Shares of 24,085 Vir Biotechnology, Inc. (NASDAQ:VIR)

XTX Topco Ltd acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 24,085 shares of the company’s stock, valued at approximately $177,000.

A number of other institutional investors and hedge funds have also bought and sold shares of VIR. SBI Securities Co. Ltd. purchased a new position in Vir Biotechnology in the 4th quarter worth $60,000. PNC Financial Services Group Inc. raised its position in Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,999 shares during the period. KBC Group NV raised its position in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc purchased a new position in Vir Biotechnology in the 4th quarter worth $74,000. Finally, Virtu Financial LLC purchased a new position in Vir Biotechnology in the 4th quarter worth $94,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VIR has been the topic of a number of analyst reports. Leerink Partners lifted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price objective on shares of Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, April 17th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.57.

Insider Buying and Selling

In related news, CEO Backer Marianne De sold 79,712 shares of the business’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the sale, the chief executive officer now owns 769,505 shares of the company’s stock, valued at $4,578,554.75. The trade was a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the sale, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 99,611 shares of company stock valued at $663,525 over the last quarter. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Trading Down 0.3 %

Shares of VIR opened at $6.10 on Tuesday. The firm’s 50-day moving average price is $6.83 and its 200-day moving average price is $8.05. The firm has a market capitalization of $842.19 million, a price-to-earnings ratio of -1.56 and a beta of 1.14. Vir Biotechnology, Inc. has a 1-year low of $4.95 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. The firm had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).